Moxifloxacin 0.3mg/0.3ml solution for injection pre-filled syringes

200mg/100ml

Ciprofloxacin 400mg/200ml infusion polyethylene bottles

400mg/200ml

Moxifloxacin 400mg/250ml infusion polyethylene bottles

400mg/250ml

Levofloxacin 500mg/100ml infusion polyethylene bottles

500mg/100ml

Levofloxacin 125mg/5ml oral solution

Oral solution

125mg/5ml

Drug monograph — bnf.nice.org.uk

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Clinical guidelines and formulary information

British National Formulary

Moxifloxacin

BNF

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

ES37

Evidence summary

Updated Aug 2021

Cellulitis and erysipelas: antimicrobial prescribing (NG141)

NG141

Guidance

Updated Sept 2019

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

NG114

Guidance

Updated Dec 2018

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Moxifloxacin

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

23349111000001109

dm+d ID

23349111000001109

VTM (Virtual Therapeutic Moiety)

776831003

VMP (Virtual Medicinal Product)

23349111000001109

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

J01MA14

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

1 found

Half-life

11.5-15.6 hours

Mechanism

The bactericidal action of moxifloxacin results from inhibition of the enzymes t…

Food interactions

2 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

90%

Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.

Half-life

11.5-15.6 hours

11.5-15.6 hours (single dose, oral)

Protein binding

50%

50% bound to serum proteins, independent of drug concentration.

Volume of distribution

1.7 to 2.7 L/kg

* 1.7 to 2.7 L/kg

Metabolism

52%

Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation.…

Elimination

45%

Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).

Clearance

2 L/h

* 12 +/- 2 L/hr

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Properties:

solid

Avg. mass: 401.43 Da

View FDA drug label

DrugBank indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Also known as(32)

1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid

Moxifloxacin

Moxifloxacine

Moxifloxacino

5.6.2.2

5.99.1.3

5.6.2.2

5.99.1.3

Dosage forms(73)

Solution (Ophthalmic) — 0.5 % w/v

Injection (Intravenous) — 0.16 %

Tablet (Oral) — 400 mg

Tablet, film coated (Oral) — 436.8 Mg

Solution (Parenteral) — 400 mg/250ml

Tablet, film coated (Oral) — 400 mg/1

Solution (Intravenous) — 400 mg / 250 mL

Solution — 400 mg/250ml

Molecular properties(19)

Drug interactions(945)

Known interactions with other medications. Always consult a healthcare professional.

Ivabradine

Moderate

DB09083

Ivabradine may increase the QTc-prolonging activities of Moxifloxacin.

Didanosine

Moderate

DB00900

Didanosine can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Probenecid

Moderate

DB01032

Probenecid may decrease the excretion rate of Moxifloxacin which could result in a higher serum level.

Quinapril

Moderate

DB00881

Quinapril can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium acetate

Moderate

DB00258

Calcium acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Sevelamer

Moderate

DB00658

Sevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Iron Dextran

Moderate

DB00893

Iron Dextran can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium

Moderate

DB01373

Calcium can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Lanthanum carbonate

Moderate

DB06792

Lanthanum carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric carboxymaltose

Moderate

DB08917

Ferric carboxymaltose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Iron sucrose

Moderate

DB09146

Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric pyrophosphate

Moderate

DB09147

Ferric pyrophosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric sulfate

Moderate

DB11171

Ferric sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric cation

Moderate

DB13949

Ferric cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Tetraferric tricitrate decahydrate

Moderate

DB14520

Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Lanthanum III cation

Moderate

DB14579

Lanthanum III cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric oxyhydroxide

Moderate

DB14695

Ferric oxyhydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Sucralfate

Moderate

DB00364

Sucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Zolmitriptan

Moderate

DB00315

The metabolism of Zolmitriptan can be decreased when combined with Moxifloxacin.

Nitrofurantoin

Moderate

DB00698

The therapeutic efficacy of Moxifloxacin can be decreased when used in combination with Nitrofurantoin.

Agomelatine

Unknown severity

DB06594

The serum concentration of Agomelatine can be increased when it is combined with Moxifloxacin.

Pirfenidone

Moderate

DB04951

The metabolism of Pirfenidone can be decreased when combined with Moxifloxacin.

Tizanidine

Unknown severity

DB00697

The serum concentration of Tizanidine can be increased when it is combined with Moxifloxacin.

Mycophenolate mofetil

Unknown severity

DB00688

The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Moxifloxacin.

Mycophenolic acid

Unknown severity

DB01024

The serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.

Picosulfuric acid

Moderate

DB09268

The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.

Insulin human

Moderate

DB00030

The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.

Insulin lispro

Moderate

DB00046

The therapeutic efficacy of Insulin lispro can be increased when used in combination with Moxifloxacin.

Insulin pork

Moderate

DB00071

The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.

Troglitazone

Moderate

DB00197

The therapeutic efficacy of Troglitazone can be increased when used in combination with Moxifloxacin.

Glimepiride

Moderate

DB00222

The therapeutic efficacy of Glimepiride can be increased when used in combination with Moxifloxacin.

Sulfisoxazole

Moderate

DB00263

The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Moxifloxacin.

Acarbose

Moderate

DB00284

The therapeutic efficacy of Acarbose can be increased when used in combination with Moxifloxacin.

Metformin

Moderate

DB00331

The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.

Sulfadiazine

Moderate

DB00359

The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Moxifloxacin.

Rosiglitazone

Moderate

DB00412

The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Moxifloxacin.

Acetohexamide

Moderate

DB00414

The therapeutic efficacy of Acetohexamide can be increased when used in combination with Moxifloxacin.

Miglitol

Moderate

DB00491

The therapeutic efficacy of Miglitol can be increased when used in combination with Moxifloxacin.

Chlorpropamide

Moderate

DB00672

The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Moxifloxacin.

Nateglinide

Moderate

DB00731

The therapeutic efficacy of Nateglinide can be increased when used in combination with Moxifloxacin.

Pentamidine

Moderate

DB00738

The therapeutic efficacy of Pentamidine can be increased when used in combination with Moxifloxacin.

Tolazamide

Moderate

DB00839

The therapeutic efficacy of Tolazamide can be increased when used in combination with Moxifloxacin.

Repaglinide

Moderate

DB00912

The therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin.

Phenformin

Moderate

DB00914

The therapeutic efficacy of Phenformin can be increased when used in combination with Moxifloxacin.

Sulfamethoxazole

Moderate

DB01015

The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Moxifloxacin.

Glyburide

Moderate

DB01016

The therapeutic efficacy of Glyburide can be increased when used in combination with Moxifloxacin.

Glipizide

Moderate

DB01067

The therapeutic efficacy of Glipizide can be increased when used in combination with Moxifloxacin.

Gliclazide

Moderate

DB01120

The therapeutic efficacy of Gliclazide can be increased when used in combination with Moxifloxacin.

Tolbutamide

Moderate

DB01124

The therapeutic efficacy of Tolbutamide can be increased when used in combination with Moxifloxacin.

Pioglitazone

Moderate

DB01132

The therapeutic efficacy of Pioglitazone can be increased when used in combination with Moxifloxacin.